Home › Funds › CHELSEA COUNSEL CO › PRME
CHELSEA COUNSEL CO position in PRME
PRIME MEDICINE INC · Health Care
CHELSEA COUNSEL CO reported holding 448,010 shares of PRME (PRIME MEDICINE INC) in its Q3 2026 13F filing — a position valued at US$1.4M, representing 0.58% of its reported portfolio and ranking #39 among its reported holdings. CHELSEA COUNSEL CO has disclosed PRME holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How CHELSEA COUNSEL CO's PRME position evolved
CHELSEA COUNSEL CO first disclosed a stake in PRME in Q3 2023 at 600 shares (US$6K). The position peaked in Q2 2026 at 449,060 shares, worth US$1.7M. Across 13 filings, CHELSEA COUNSEL CO increased the stake 7 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 448,010 shares valued at US$1.4M. Notable position changes include a 733% increase in Q4 2023 (shares fell 21% over the following quarter), a 1454% increase in Q2 2024 (shares fell 25% over the following quarter), a 137% increase in Q4 2024 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 600 | $5.72K | New |
| Q4 2023 | 5.00K | $44.30K | Add |
| Q1 2024 | 5.00K | $35.00K | Hold |
| Q2 2024 | 77.69K | $399.33K | Add |
| Q3 2024 | 78.69K | $304.53K | Add |
| Q4 2024 | 186.78K | $545.40K | Add |
| Q1 2025 | 208.21K | $414.34K | Add |
| Q2 2025 | 208.21K | $514.28K | Hold |
| Q3 2025 | 208.21K | $1.15M | Hold |
| Q4 2025 | 227.00K | $787.69K | Add |
| Q1 2026 | 462.34K | $1.61M | Add |
| Q2 2026 | 449.06K | $1.66M | Reduce |
| Q3 2026 | 448.01K | $1.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PRME and 13F data
PRME (PRIME MEDICINE INC) is a Health Care company. 35 other funds we track also report a position in PRME — the largest reported positions include Alphabet Inc. (US$50.7M), Casdin Capital (US$11.7M), Redmile Group, LLC (US$5.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PRME
- Alphabet Inc. 16.56M sh · $50.68M · Q3 2026
- Casdin Capital 3.17M sh · $11.69M · Q2 2026
- Redmile Group, LLC 1.39M sh · $5.13M · Q2 2026
- Alessandra Capital Management, LLC 800.77K sh · $2.45M · Q3 2026
More on CHELSEA COUNSEL CO
FAQ
How long has CHELSEA COUNSEL CO held PRME?
CHELSEA COUNSEL CO has disclosed PRME holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is CHELSEA COUNSEL CO's current position in PRME?
As of Q3 2026, CHELSEA COUNSEL CO holds 448.01K shares of PRME (PRIME MEDICINE INC), valued at $1.37M, representing 0.58% of its reported portfolio and ranking #39.
Has CHELSEA COUNSEL CO been buying or selling PRME?
In the latest 13F filing (Q3 2026), CHELSEA COUNSEL CO held unchanged its position in PRME. The position peaked in Q2 2026 at 449.06K shares.
Which other funds hold PRME?
Other major institutional holders of PRME include Alphabet Inc., Casdin Capital, Redmile Group, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.